Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials
Abstract Background Schizophrenia is a complex psychiatric disorder characterized by positive, negative, and cognitive symptoms. KarXT, a novel combination of xanomeline and trospium, offers potential therapeutic benefits for schizophrenia treatment by targeting muscarinic receptors and avoiding dop...
Gardado en:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMC
2025-03-01
|
| Series: | BMC Psychiatry |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1186/s12888-025-06696-5 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|